A detailed history of Farallon Capital Management LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Farallon Capital Management LLC holds 28,000 shares of PCVX stock, worth $2.41 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
28,000
Previous 290,000 90.34%
Holding current value
$2.41 Million
Previous $21.9 Million 85.4%
% of portfolio
0.02%
Previous 0.11%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$70.52 - $117.12 $18.5 Million - $30.7 Million
-262,000 Reduced 90.34%
28,000 $3.2 Million
Q2 2024

Aug 14, 2024

SELL
$60.06 - $78.77 $5.25 Million - $6.88 Million
-87,400 Reduced 23.16%
290,000 $21.9 Million
Q1 2024

May 15, 2024

BUY
$59.79 - $81.05 $22.4 Million - $30.3 Million
374,000 Added 11000.0%
377,400 $25.8 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $154,190 - $215,594
3,400 New
3,400 $213,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.1B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Farallon Capital Management LLC Portfolio

Follow Farallon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.